Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Open label extension (OLE) study is progressing with all 7 sites activated; interim data planned for Q4 2024Selected by Food...
Open label extension (OLE) study is progressing with all 7 sites activated; interim data planned for Q4 2024Selected by Food...
LOS ANGELES, Aug. 7, 2024 /PRNewswire/ -- SprintRay is excited to announce The Midas Restoration Tour, an event series to...
PALO ALTO, CA / ACCESSWIRE / August 7, 2024 / Bioz, Inc., a pioneer in AI-driven research solutions, is excited...
STOCKHOLM, SE / ACCESSWIRE / August 07, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a...